サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1463879

リキッドバイオプシー市場- 世界の産業規模、シェア、動向、機会、予測、オファリング別、技術別、ワークフロー別、サンプル別、循環バイオマーカー別、用途別、エンドユーザー別、地域別、競合別、2019年～2029年

Liquid Biopsy Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Offering, By Technology, By Workflow, By Sample, By Circulating Biomarkers, By Application, By End User, By Region and Competition, 2019-2029F

出版日
ページ情報
英文 185 Pages
納期
2～3営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円

こちらのレポートには、数時間（ご購入金額の10%）分のアナリストへの質問／追加調査サービスが含まれております。

リキッドバイオプシー市場- 世界の産業規模、シェア、動向、機会、予測、オファリング別、技術別、ワークフロー別、サンプル別、循環バイオマーカー別、用途別、エンドユーザー別、地域別、競合別、2019年～2029年
出版日: 2024年04月15日
発行: TechSci Research
ページ情報: 英文 185 Pages
納期: 2～3営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

世界のリキッドバイオプシー市場は2023年に43億8,000万米ドルと評価され、2029年まで12.41%の目覚ましい成長が予測されています。

世界のリキッドバイオプシー市場は、いくつかの重要な要因によって急速な成長を遂げています。これには、非侵襲的診断技術に対する需要の増加、アッセイ精度を高める技術の進歩、がんや慢性疾患の有病率の上昇、がん以外の用途の拡大などが含まれます。支持的な規制の枠組み、償還政策、研究開発への投資が市場拡大をさらに後押ししています。臨床ニーズ、技術革新、規制当局の支援の融合は、リキッドバイオプシー技術を通じて疾患検出、モニタリング、治療成績を改善する大きな機会を市場関係者にもたらします。

主要市場促進要因

非侵襲的診断ツールに対する需要の高まり

ゲノム解析技術の進歩

がんと慢性疾患の有病率の上昇

支持的な規制枠組みおよび償還政策

主な市場課題

コストと償還の課題

サンプルの品質と分析前の変数

主要市場動向

リキッドバイオプシーの標準化と品質管理への注力

ポイントオブケア（POC）と分散型検査の台頭

セグメント別の洞察

オファリング別の洞察

技術別の洞察

地域別の洞察

目次

第1章 概要

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 顧客の声

第5章 臨床試験分析

第6章 特許分析

第7章 世界のリキッドバイオプシー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • オファリング別（検査サービス、キット、プラットフォーム、その他消耗品）
    • 技術別（ポリメラーゼ連鎖反応、次世代シーケンス、その他）
    • ワークフロー別（サンプル調製、ライブラリー調製、シーケンス、データ解析管理）
    • サンプル別（血液、尿、唾液、その他）
    • 循環バイオマーカー別（循環腫瘍細胞（CTC）、遊離核酸、エクソソーム細胞外小胞、その他）
    • 用途別（腫瘍学、非腫瘍学）
    • エンドユーザー別（臨床研究所、学術調査機関、製薬バイオテクノロジー企業）
    • 企業別（2023年）
    • 地域別
  • 市場マップ

第8章 北米のリキッドバイオプシー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • オファリング別
    • 技術別
    • ワークフロー別
    • サンプル別
    • 循環バイオマーカー別
    • 用途別
    • エンドユーザー別
    • 国別
  • 北米国別分析
    • 米国
    • メキシコ
    • カナダ

第9章 欧州のリキッドバイオプシー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • オファリング別
    • 技術別
    • ワークフロー別
    • サンプル別
    • 循環バイオマーカー別
    • 用途別
    • エンドユーザー別
    • 国別
  • 欧州国別分析
    • フランス
    • ドイツ
    • 英国
    • イタリア
    • スペイン

第10章 アジア太平洋のリキッドバイオプシー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • オファリング別
    • 技術別
    • ワークフロー別
    • サンプル別
    • 循環バイオマーカー別
    • 用途別
    • エンドユーザー別
    • 国別
  • アジア太平洋地域国別分析
    • 中国
    • インド
    • 韓国
    • 日本
    • オーストラリア

第11章 南米のリキッドバイオプシー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • オファリング別
    • 技術別
    • ワークフロー別
    • サンプル別
    • 循環バイオマーカー別
    • 用途別
    • エンドユーザー別
    • 国別
  • 南米：国別分析
    • ブラジル
    • アルゼンチン
    • コロンビア

第12章 中東・アフリカのリキッドバイオプシー市場展望

  • 市場規模予測
    • 金額別
  • 市場シェア予測
    • オファリング別
    • 技術別
    • ワークフロー別
    • サンプル別
    • 循環バイオマーカー別
    • 用途別
    • エンドユーザー別
    • 国別
  • MEA：国別分析
    • 南アフリカ
    • サウジアラビア
    • アラブ首長国連邦

第13章 市場力学

  • 促進要因
  • 課題

第14章 市場動向と発展

  • 合併買収（もしあれば）
  • 製品上市（もしあれば）
  • 最近の動向

第15章 ポーターのファイブフォース分析

  • 業界内の競合
  • 新規参入の可能性
  • サプライヤーの力
  • 顧客の力
  • 代替品の脅威

第16章 競合情勢

  • F. Hoffmann-La Roche Ltd
  • Thermo Fisher Scientific, Inc.
  • PerkinElmer Inc.
  • LungLife AI, Inc.
  • Illumina, Inc.
  • QIAGEN NV
  • NeoGenomics Laboratories, Inc.
  • Myriad Genetics, Inc.
  • Bio-Rad Laboratories, Inc.
  • Guardent Health Inc.
  • Natera, Inc.
  • Sysmex Corporation
  • Abcodia Ltd.
  • Dxcover Limited

第17章 戦略的提言

第18章 免責事項

目次
Product Code: 12950

Global Liquid Biopsy Market was valued at USD 4.38 Billion in 2023 and is anticipated to project impressive growth of 12.41% through 2029. Global Liquid Biopsy Market is experiencing rapid growth driven by several key factors. These include the increasing demand for non-invasive diagnostic techniques, technological advancements enhancing assay accuracy, the rising prevalence of cancer and chronic diseases, and expanding applications beyond oncology. Supportive regulatory frameworks, reimbursement policies, and investments in research and development further fuel market expansion. The convergence of clinical need, technological innovation, and regulatory support presents significant opportunities for market players to improve disease detection, monitoring, and treatment outcomes through liquid biopsy technologies.

Key Market Drivers

Growing Demand for Non-Invasive Diagnostic Tools

Global Liquid Biopsy Market is propelled by an escalating demand for non-invasive diagnostic methods across various medical fields. Liquid biopsy, characterized by its minimally invasive nature and ability to analyze biomarkers circulating in bodily fluids, offers a revolutionary approach to disease detection and monitoring. Particularly in oncology, where early detection is critical for improved patient outcomes, liquid biopsy holds immense promise. By detecting and analyzing circulating tumor cells (CTCs), cell-free DNA (cfDNA), and other biomolecules, liquid biopsy provides valuable insights into disease progression, treatment response, and the emergence of drug resistance. This demand for non-invasive diagnostic tools is fueled by a growing recognition of the limitations and invasiveness of traditional tissue biopsies, driving healthcare providers and patients alike to seek alternatives that offer greater convenience and reduced risk.

Technological Advancements in Genomic Analysis

Technological advancements in genomic analysis, molecular biology, and bioinformatics are driving significant advancements in the Global Liquid Biopsy Market. These innovations have led to the development of highly sensitive and specific liquid biopsy assays capable of detecting minute quantities of circulating biomarkers with unprecedented accuracy. Next-generation sequencing (NGS) and digital PCR platforms have revolutionized liquid biopsy-based genomic profiling, enabling comprehensive analysis of genetic alterations such as mutations, copy number variations, and chromosomal rearrangements. These advancements not only enhance the diagnostic capabilities of liquid biopsy but also enable the monitoring of disease dynamics in real-time, facilitating personalized treatment strategies tailored to individual patients' molecular profiles.

Rising Prevalence of Cancer and Chronic Diseases

The increasing prevalence of cancer and chronic diseases worldwide is driving the adoption of liquid biopsy technologies. With cancer rates on the rise globally and chronic diseases such as cardiovascular disorders and neurodegenerative conditions posing significant public health challenges, there is a growing need for effective diagnostic and monitoring tools. Liquid biopsy offers a minimally invasive and repeatable method for disease assessment, particularly valuable in cancer management, where serial monitoring of disease progression and treatment response is essential. Additionally, liquid biopsy has applications beyond oncology, including prenatal screening, infectious disease monitoring, transplant rejection monitoring, and drug development, further expanding its market potential. As the burden of cancer and chronic diseases continues to grow, the demand for liquid biopsy technologies is expected to increase, driving market growth in the coming years.

Supportive Regulatory Frameworks and Reimbursement Policies

Supportive regulatory frameworks and reimbursement policies are essential drivers of growth in the Global Liquid Biopsy Market, facilitating the adoption of innovative diagnostic technologies that promise to revolutionize disease diagnosis and management. Governments worldwide are increasingly recognizing the potential of liquid biopsy technologies to improve patient outcomes and healthcare delivery, prompting concerted efforts to streamline regulatory processes and reimbursement policies.

Regulatory bodies are playing a pivotal role in this regard by expediting approval processes for liquid biopsy assays, ensuring that these tests meet stringent standards of safety, efficacy, and quality. By accelerating the regulatory approval timeline, regulatory agencies are enabling faster market entry for liquid biopsy products, thereby expediting their availability to patients and healthcare providers.

Furthermore, governments are updating reimbursement policies to encompass liquid biopsy tests, ensuring that patients have greater access to these innovative diagnostic tools. Reimbursement coverage for liquid biopsy tests reduces financial barriers for patients and healthcare providers, making these tests more accessible and affordable. As a result, patients can benefit from timely and accurate disease diagnosis, leading to improved treatment outcomes and quality of life.

Key Market Challenges

Cost and Reimbursement Challenges

Cost and reimbursement challenges pose significant barriers to the adoption of liquid biopsy tests in clinical practice. While liquid biopsy offers the potential for non-invasive and real-time monitoring of disease progression, the high cost of assay development, validation, and implementation can limit patient access and healthcare provider adoption. Additionally, reimbursement policies may lag behind technological advancements, leading to disparities in coverage and reimbursement rates for liquid biopsy tests. Addressing these challenges requires collaboration between industry stakeholders, policymakers, and payers to develop sustainable reimbursement models that ensure equitable access to liquid biopsy technologies for patients.

Sample Quality and Pre-Analytical Variables

Global Liquid Biopsy Market faces a significant hurdle stemming from the variability in sample quality and pre-analytical variables. Sample collection, processing, and storage conditions can greatly influence the integrity and stability of circulating biomarkers present in liquid biopsy samples, potentially leading to inaccurate test results and diagnostic errors.

Various factors contribute to this variability, including differences in blood collection techniques, the use of different types of blood collection tubes, variations in processing methods, and delays in sample transportation to testing laboratories. These factors can introduce inconsistencies in sample handling and processing, compromising the reliability and reproducibility of liquid biopsy assays.

For instance, improper blood collection techniques or the use of suboptimal blood collection tubes may result in hemolysis, leading to the release of intracellular components that can interfere with biomarker analysis. Similarly, delays in sample processing or storage at incorrect temperatures can degrade circulating biomarkers, reducing their detectability and compromising assay accuracy.

Key Market Trends

Focus on Liquid Biopsy Standardization and Quality Control

Standardization and quality control measures are becoming increasingly important in the Global Liquid Biopsy Market to ensure the reliability and reproducibility of test results. Efforts are underway to establish standardized protocols for sample collection, processing, and analysis, as well as quality control measures to monitor assay performance and minimize variability. Standardization initiatives aim to enhance the accuracy and comparability of liquid biopsy test results across different laboratories and testing platforms, fostering confidence among clinicians and patients in the reliability of liquid biopsy-based diagnostics.

Rise of Point-of-Care (POC) and Decentralized Testing

The rise of point-of-care (POC) and decentralized testing is a notable trend in the Global Liquid Biopsy Market, spurred by the demand for rapid and accessible diagnostic solutions. POC and decentralized testing platforms revolutionize the landscape of liquid biopsy diagnostics by enabling real-time analysis of liquid biopsy samples directly at or near the patient's location. This approach eliminates the need for centralized laboratory facilities and significantly reduces turnaround times for obtaining test results.

These innovative platforms offer immense potential for expanding access to liquid biopsy-based diagnostics, particularly in resource-limited settings, remote geographical areas, and point-of-care settings such as clinics, ambulatory care centers, and community health centers. By bringing diagnostic capabilities closer to patients, POC and decentralized testing overcome geographical barriers and enhance healthcare accessibility for underserved populations.

Moreover, POC and decentralized testing play a crucial role in facilitating timely decision-making and treatment initiation, especially in urgent clinical scenarios where rapid diagnostic turnaround is paramount for effective patient management. By providing actionable insights into disease status and treatment response in real-time, these platforms empower healthcare providers to make informed decisions promptly, optimizing patient outcomes and healthcare efficiency.

Segmental Insights

Offering Insights

Based on the Offering, testing services emerged as the dominant segment in 2023. Testing services encompass a wide range of diagnostic procedures and analytical services offered by specialized laboratories and diagnostic centers. These services typically involve the collection, processing, analysis, and interpretation of liquid biopsy samples to detect and monitor biomarkers associated with various diseases, including cancer.

Testing services play a pivotal role in facilitating the adoption of liquid biopsy technologies in clinical practice, as they provide healthcare providers with access to expertise, infrastructure, and resources required for accurate and reliable testing. Additionally, outsourcing liquid biopsy testing to specialized laboratories allows healthcare providers to leverage advanced technologies, such as next-generation sequencing (NGS) and digital PCR, which may not be readily available in-house. Testing services offer scalability and flexibility, enabling healthcare providers to tailor testing protocols to meet the specific needs of patients and clinical scenarios. This includes the ability to perform serial monitoring of disease progression, treatment response, and the emergence of drug resistance, providing valuable insights for personalized treatment planning and clinical decision-making.

Technology Insights

Based on the Technology, Next Generation Sequencing (NGS) emerges as the fastest growing segment. NGS, also known as high-throughput sequencing, revolutionizes the analysis of liquid biopsy samples by enabling the simultaneous sequencing of millions of DNA fragments in a single run. This technology offers unparalleled sensitivity, specificity, and scalability, allowing for comprehensive genomic profiling of circulating biomarkers such as circulating tumor DNA (ctDNA) and circulating tumor cells (CTCs).

NGS enables the detection of genetic alterations, including mutations, copy number variations, and chromosomal rearrangements, with high precision and accuracy. This capability is particularly valuable in oncology, where liquid biopsy-based genomic profiling can provide insights into tumor heterogeneity, clonal evolution, and the emergence of drug resistance. Additionally, NGS allows for the detection of rare and low-frequency mutations, enhancing the sensitivity of liquid biopsy assays for early cancer detection and treatment monitoring.

Regional Insights

North America emerged as the dominant region in the Global Liquid Biopsy Market. The region's leadership is driven by several key factors contributing to its remarkable market share and growth trajectory. North America boasts a robust healthcare infrastructure characterized by advanced medical facilities, cutting-edge research institutions, and a highly skilled workforce. This conducive environment fosters innovation and facilitates the development and adoption of novel diagnostic technologies such as liquid biopsy.

North America is home to a significant number of leading biotechnology and pharmaceutical companies actively engaged in the research, development, and commercialization of liquid biopsy products. These companies leverage the region's strong research ecosystem, access to capital, and supportive regulatory environment to drive innovation and bring new liquid biopsy assays to market. The region's favorable reimbursement landscape and widespread adoption of personalized medicine contribute to the widespread acceptance and utilization of liquid biopsy technologies in clinical practice. Reimbursement policies in North America often provide coverage for liquid biopsy tests, ensuring patient access and affordability, which further fuels market growth.

Key Market Players

F. Hoffmann-La Roche Ltd.

Thermo Fisher Scientific, Inc.

PerkinElmer Inc.

LungLife AI, Inc.

Illumina, Inc.

QIAGEN NV

NeoGenomics Laboratories, Inc.

Myriad Genetics, Inc.

Bio-Rad Laboratories, Inc.

Guardant Health Inc.

Natera, Inc.

Sysmex Corporation

Abcodia Ltd.

Dxcover Limited

Report Scope:

In this report, the Global Liquid Biopsy Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Liquid Biopsy Market,By Offering:

  • Testing Services
  • Kits
  • Platform
  • Other Consumables

Liquid Biopsy Market,By Technology:

  • Polymerase Chain Reaction (PCR)
  • Next Generation Sequencing (NGS)
  • Others

Liquid Biopsy Market,By Workflow:

  • Sample Preparation
  • Library Preparation
  • Sequencing
  • Data Analysis Management

Liquid Biopsy Market,By Sample:

  • Blood
  • Urine
  • Saliva
  • Others

Liquid Biopsy Market,By Circulating Biomarkers:

  • Circulating Tumor Cells (CTCs)
  • Cell-free Nucleic Acids
  • Exosomes Extracellular Vesicles

Liquid Biopsy Market,By Application:

  • Oncological
  • Non-oncological

Liquid Biopsy Market,By End User:

  • Clinical Laboratories
  • Academic Research Institutes
  • Pharmaceutical Biotechnology Companies

Liquid Biopsy Market, By Region:

  • North America
    • United States
    • Canada
    • Mexico
  • Europe
    • France
    • United Kingdom
    • Italy
    • Germany
    • Spain
  • Asia-Pacific
    • China
    • India
    • Japan
    • Australia
    • South Korea
  • South America
    • Brazil
    • Argentina
    • Colombia
  • Middle East Africa
    • South Africa
    • Saudi Arabia
    • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Liquid Biopsy Market.

Available Customizations:

Global Liquid Biopsy market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1.Product Overview

  • 1.1.Market Definition
  • 1.2.Scope of the Market
    • 1.2.1.Markets Covered
    • 1.2.2.Years Considered for Study
    • 1.2.3.Key Market Segmentations

2.Research Methodology

  • 2.1.Objective of the Study
  • 2.2.Baseline Methodology
  • 2.3.Key Industry Partners
  • 2.4.Major Association and Secondary Sources
  • 2.5.Forecasting Methodology
  • 2.6.Data Triangulation Validation
  • 2.7.Assumptions and Limitations

3.Executive Summary

  • 3.1.Overview of the Market
  • 3.2.Overview of Key Market Segmentations
  • 3.3.Overview of Key Market Players
  • 3.4.Overview of Key Regions/Countries
  • 3.5.Overview of Market Drivers, Challenges, and Trends

4.Voice of Customer

5.Clinical Trial Analysis

6.Patent Analysis

7.Global Liquid Biopsy Market Outlook

  • 7.1.Market Size Forecast
    • 7.1.1.By Value
  • 7.2.Market Share Forecast
    • 7.2.1.By Offering (Testing Service, Kits, Platform, Other Consumables)
    • 7.2.2.By Technology (Polymerase Chain Reactions, Next Generation Sequencing, Others)
    • 7.2.3.By Workflow (Sample Preparation, Library Preparation, Sequencing, Data Analysis Management)
    • 7.2.4.By Sample (Blood, Urine, Saliva, Others)
    • 7.2.5.By Circulating Biomarker (Circulating Tumor Cells (CTCs), Cell Free Nucleic Acids, Exosomes Extracellular Vesicles, Others)
    • 7.2.6.By Application (Oncological and non-Oncological)
      • 7.2.6.1.By Oncological (Breast Cancer, Lung Cancer, Prostate Cancer, Colorectal Cancer, Others)
      • 7.2.6.2.By Non-Oncological (Treatment Monitoring, Prognosis Recurrence Monitoring, Treatment Selection, Others)
    • 7.2.7.By End User (Clinical Laboratories, Academic Research Institutes, Pharmaceutical Biotechnology Companies)
    • 7.2.8.By Company (2023)
    • 7.2.9.By Region
  • 7.3.Market Map

8.North America Liquid Biopsy Market Outlook

  • 8.1.Market Size Forecast
    • 8.1.1.By Value
  • 8.2.Market Share Forecast
    • 8.2.1.By Offering
    • 8.2.2.By Technology
    • 8.2.3.By Workflow
    • 8.2.4.By Sample
    • 8.2.5.By Circulating Biomarker
    • 8.2.6.By Application
    • 8.2.7.By End User
    • 8.2.8.By Country
  • 8.3.North America: Country Analysis
    • 8.3.1.United States Liquid Biopsy Market Outlook
      • 8.3.1.1.Market Size Forecast
        • 8.3.1.1.1.By Value
      • 8.3.1.2.Market Share Forecast
        • 8.3.1.2.1.By Offering
        • 8.3.1.2.2.By Technology
        • 8.3.1.2.3.By Workflow
        • 8.3.1.2.4.By Sample
        • 8.3.1.2.5.By Circulating Biomarker
        • 8.3.1.2.6.By Application
        • 8.3.1.2.7.By End User
    • 8.3.2.Mexico Liquid Biopsy Market Outlook
      • 8.3.2.1.Market Size Forecast
        • 8.3.2.1.1.By Value
      • 8.3.2.2.Market Share Forecast
        • 8.3.2.2.1.By Offering
        • 8.3.2.2.2.By Technology
        • 8.3.2.2.3.By Workflow
        • 8.3.2.2.4.By Sample
        • 8.3.2.2.5.By Circulating Biomarker
        • 8.3.2.2.6.By Application
        • 8.3.2.2.7.By End User
    • 8.3.3.Canada Liquid Biopsy Market Outlook
      • 8.3.3.1.Market Size Forecast
        • 8.3.3.1.1.By Value
      • 8.3.3.2.Market Share Forecast
        • 8.3.3.2.1.By Offering
        • 8.3.3.2.2.By Technology
        • 8.3.3.2.3.By Workflow
        • 8.3.3.2.4.By Sample
        • 8.3.3.2.5.By Circulating Biomarker
        • 8.3.3.2.6.By Application
        • 8.3.3.2.7.By End User

9.Europe Liquid Biopsy Market Outlook

  • 9.1.Market Size Forecast
    • 9.1.1.By Value
  • 9.2.Market Share Forecast
    • 9.2.1.By Offering
    • 9.2.2.By Technology
    • 9.2.3.By Workflow
    • 9.2.4.By Sample
    • 9.2.5.By Circulating Biomarker
    • 9.2.6.By Application
    • 9.2.7.By End User
    • 9.2.8.By Country
  • 9.3.Europe: Country Analysis
    • 9.3.1.France Liquid Biopsy Market Outlook
      • 9.3.1.1.Market Size Forecast
        • 9.3.1.1.1.By Value
      • 9.3.1.2.Market Share Forecast
        • 9.3.1.2.1.By Offering
        • 9.3.1.2.2.By Technology
        • 9.3.1.2.3.By Workflow
        • 9.3.1.2.4.By Sample
        • 9.3.1.2.5.By Circulating Biomarker
        • 9.3.1.2.6.By Application
        • 9.3.1.2.7.By End User
    • 9.3.2.Germany Liquid Biopsy Market Outlook
      • 9.3.2.1.Market Size Forecast
        • 9.3.2.1.1.By Value
      • 9.3.2.2.Market Share Forecast
        • 9.3.2.2.1.By Offering
        • 9.3.2.2.2.By Technology
        • 9.3.2.2.3.By Workflow
        • 9.3.2.2.4.By Sample
        • 9.3.2.2.5.By Circulating Biomarker
        • 9.3.2.2.6.By Application
        • 9.3.2.2.7.By End User
    • 9.3.3.United Kingdom Liquid Biopsy Market Outlook
      • 9.3.3.1.Market Size Forecast
        • 9.3.3.1.1.By Value
      • 9.3.3.2.Market Share Forecast
        • 9.3.3.2.1.By Offering
        • 9.3.3.2.2.By Technology
        • 9.3.3.2.3.By Workflow
        • 9.3.3.2.4.By Sample
        • 9.3.3.2.5.By Circulating Biomarker
        • 9.3.3.2.6.By Application
        • 9.3.3.2.7.By End User
    • 9.3.4.Italy Liquid Biopsy Market Outlook
      • 9.3.4.1.Market Size Forecast
        • 9.3.4.1.1.By Value
      • 9.3.4.2.Market Share Forecast
        • 9.3.4.2.1.By Offering
        • 9.3.4.2.2.By Technology
        • 9.3.4.2.3.By Workflow
        • 9.3.4.2.4.By Sample
        • 9.3.4.2.5.By Circulating Biomarker
        • 9.3.4.2.6.By Application
        • 9.3.4.2.7.By End User
    • 9.3.5.Spain Liquid Biopsy Market Outlook
      • 9.3.5.1.Market Size Forecast
        • 9.3.5.1.1.By Value
      • 9.3.5.2.Market Share Forecast
        • 9.3.5.2.1.By Offering
        • 9.3.5.2.2.By Technology
        • 9.3.5.2.3.By Workflow
        • 9.3.5.2.4.By Sample
        • 9.3.5.2.5.By Circulating Biomarker
        • 9.3.5.2.6.By Application
        • 9.3.5.2.7.By End User

10.Asia-Pacific Liquid Biopsy Market Outlook

  • 10.1.Market Size Forecast
    • 10.1.1.By Value
  • 10.2.Market Share Forecast
    • 10.2.1.By Offering
    • 10.2.2.By Technology
    • 10.2.3.By Workflow
    • 10.2.4.By Sample
    • 10.2.5.By Circulating Biomarker
    • 10.2.6.By Application
    • 10.2.7.By End User
    • 10.2.8.By Country
  • 10.3.Asia-Pacific: Country Analysis
    • 10.3.1.China Liquid Biopsy Market Outlook
      • 10.3.1.1.Market Size Forecast
        • 10.3.1.1.1.By Value
      • 10.3.1.2.Market Share Forecast
        • 10.3.1.2.1.By Offering
        • 10.3.1.2.2.By Technology
        • 10.3.1.2.3.By Workflow
        • 10.3.1.2.4.By Sample
        • 10.3.1.2.5.By Circulating Biomarker
        • 10.3.1.2.6.By Application
        • 10.3.1.2.7.By End User
    • 10.3.2.India Liquid Biopsy Market Outlook
      • 10.3.2.1.Market Size Forecast
        • 10.3.2.1.1.By Value
      • 10.3.2.2.Market Share Forecast
        • 10.3.2.2.1.By Offering
        • 10.3.2.2.2.By Technology
        • 10.3.2.2.3.By Workflow
        • 10.3.2.2.4.By Sample
        • 10.3.2.2.5.By Circulating Biomarker
        • 10.3.2.2.6.By Application
        • 10.3.2.2.7.By End User
    • 10.3.3.South Korea Liquid Biopsy Market Outlook
      • 10.3.3.1.Market Size Forecast
        • 10.3.3.1.1.By Value
      • 10.3.3.2.Market Share Forecast
        • 10.3.3.2.1.By Offering
        • 10.3.3.2.2.By Technology
        • 10.3.3.2.3.By Workflow
        • 10.3.3.2.4.By Sample
        • 10.3.3.2.5.By Circulating Biomarker
        • 10.3.3.2.6.By Application
        • 10.3.3.2.7.By End User
    • 10.3.4.Japan Liquid Biopsy Market Outlook
      • 10.3.4.1.Market Size Forecast
        • 10.3.4.1.1.By Value
      • 10.3.4.2.Market Share Forecast
        • 10.3.4.2.1.By Offering
        • 10.3.4.2.2.By Technology
        • 10.3.4.2.3.By Workflow
        • 10.3.4.2.4.By Sample
        • 10.3.4.2.5.By Circulating Biomarker
        • 10.3.4.2.6.By Application
        • 10.3.4.2.7.By End User
    • 10.3.5.Australia Liquid Biopsy Market Outlook
      • 10.3.5.1.Market Size Forecast
        • 10.3.5.1.1.By Value
      • 10.3.5.2.Market Share Forecast
        • 10.3.5.2.1.By Offering
        • 10.3.5.2.2.By Technology
        • 10.3.5.2.3.By Workflow
        • 10.3.5.2.4.By Sample
        • 10.3.5.2.5.By Circulating Biomarker
        • 10.3.5.2.6.By Application
        • 10.3.5.2.7.By End User

11.South America Liquid Biopsy Market Outlook

  • 11.1.Market Size Forecast
    • 11.1.1.By Value
  • 11.2.Market Share Forecast
    • 11.2.1.By Offering
    • 11.2.2.By Technology
    • 11.2.3.By Workflow
    • 11.2.4.By Sample
    • 11.2.5.By Circulating Biomarker
    • 11.2.6.By Application
    • 11.2.7.By End User
    • 11.2.8.By Country
  • 11.3.South America: Country Analysis
    • 11.3.1.Brazil Liquid Biopsy Market Outlook
      • 11.3.1.1.Market Size Forecast
        • 11.3.1.1.1.By Value
      • 11.3.1.2.Market Share Forecast
        • 11.3.1.2.1.By Offering
        • 11.3.1.2.2.By Technology
        • 11.3.1.2.3.By Workflow
        • 11.3.1.2.4.By Sample
        • 11.3.1.2.5.By Circulating Biomarker
        • 11.3.1.2.6.By Application
        • 11.3.1.2.7.By End User
    • 11.3.2.Argentina Liquid Biopsy Market Outlook
      • 11.3.2.1.Market Size Forecast
        • 11.3.2.1.1.By Value
      • 11.3.2.2.Market Share Forecast
        • 11.3.2.2.1.By Offering
        • 11.3.2.2.2.By Technology
        • 11.3.2.2.3.By Workflow
        • 11.3.2.2.4.By Sample
        • 11.3.2.2.5.By Circulating Biomarker
        • 11.3.2.2.6.By Application
        • 11.3.2.2.7.By End User
    • 11.3.3.Colombia Liquid Biopsy Market Outlook
      • 11.3.3.1.Market Size Forecast
        • 11.3.3.1.1.By Value
      • 11.3.3.2.Market Share Forecast
        • 11.3.3.2.1.By Offering
        • 11.3.3.2.2.By Technology
        • 11.3.3.2.3.By Workflow
        • 11.3.3.2.4.By Sample
        • 11.3.3.2.5.By Circulating Biomarker
        • 11.3.3.2.6.By Application
        • 11.3.3.2.7.By End User

12.Middle East and Africa Liquid Biopsy Market Outlook

  • 12.1.Market Size Forecast
    • 12.1.1.By Value
  • 12.2.Market Share Forecast
    • 12.2.1.By Offering
    • 12.2.2.By Technology
    • 12.2.3.By Workflow
    • 12.2.4.By Sample
    • 12.2.5.By Circulating Biomarker
    • 12.2.6.By Application
    • 12.2.7.By End User
    • 12.2.8.By Country
  • 12.3.MEA: Country Analysis
    • 12.3.1.South Africa Liquid Biopsy Market Outlook
      • 12.3.1.1.Market Size Forecast
        • 12.3.1.1.1.By Value
      • 12.3.1.2.Market Share Forecast
        • 12.3.1.2.1.By Offering
        • 12.3.1.2.2.By Technology
        • 12.3.1.2.3.By Workflow
        • 12.3.1.2.4.By Sample
        • 12.3.1.2.5.By Circulating Biomarker
        • 12.3.1.2.6.By Application
        • 12.3.1.2.7.By End User
    • 12.3.2.Saudi Arabia Liquid Biopsy Market Outlook
      • 12.3.2.1.Market Size Forecast
        • 12.3.2.1.1.By Value
      • 12.3.2.2.Market Share Forecast
        • 12.3.2.2.1.By Offering
        • 12.3.2.2.2.By Technology
        • 12.3.2.2.3.By Workflow
        • 12.3.2.2.4.By Sample
        • 12.3.2.2.5.By Circulating Biomarker
        • 12.3.2.2.6.By Application
        • 12.3.2.2.7.By End User
    • 12.3.3.UAE Liquid Biopsy Market Outlook
      • 12.3.3.1.Market Size Forecast
        • 12.3.3.1.1.By Value
      • 12.3.3.2.Market Share Forecast
        • 12.3.3.2.1.By Offering
        • 12.3.3.2.2.By Technology
        • 12.3.3.2.3.By Workflow
        • 12.3.3.2.4.By Sample
        • 12.3.3.2.5.By Circulating Biomarker
        • 12.3.3.2.6.By Application
        • 12.3.3.2.7.By End User

13.Market Dynamics

  • 13.1.Drivers
  • 13.2.Challenges

14.Market Trends Developments

  • 14.1.Merger Acquisition (If Any)
  • 14.2.Product Launches (If Any)
  • 14.3.Recent Developments

15.Porters Five Forces Analysis

  • 15.1.Competition in the Industry
  • 15.2.Potential of New Entrants
  • 15.3.Power of Suppliers
  • 15.4.Power of Customers
  • 15.5.Threat of Substitute Products

16.Competitive Landscape

  • 16.1.F. Hoffmann-La Roche Ltd
    • 16.1.1.Business Overview
    • 16.1.2.Company Snapshot
    • 16.1.3.Products Services
    • 16.1.4.Financials (As Reported)
    • 16.1.5.Recent Developments
    • 16.1.6.Key Personnel Details
    • 16.1.7.SWOT Analysis
  • 16.2.Thermo Fisher Scientific, Inc.
  • 16.3.PerkinElmer Inc.
  • 16.4.LungLife AI, Inc.
  • 16.5.Illumina, Inc.
  • 16.6.QIAGEN NV
  • 16.7.NeoGenomics Laboratories, Inc.
  • 16.8.Myriad Genetics, Inc.
  • 16.9.Bio-Rad Laboratories, Inc.
  • 16.10. Guardent Health Inc.
  • 16.11. Natera, Inc.
  • 16.12. Sysmex Corporation
  • 16.13. Abcodia Ltd.
  • 16.14. Dxcover Limited

17.Strategic Recommendations

18.About Us Disclaimer